

Completion of prospective open label clinical study of Arthrosamid® for knee osteoarthritis

October 9, 2020: Contura is pleased to announce the completion of its 12-month open label clinical study of Arthrosamid for knee osteoarthritis. The study enrolled 49 patients at three specialist treatment centres and aimed to demonstrate a significant reduction in pain in Arthrosamid treated patients with osteoarthritis of the knee. Three-month results from the study resulted in Arthrosamid being approved for sale by the company's notified body, TÜV Süd, and it is hoped that these results will be maintained for 12-months.

Commenting on the completion of the study, Patrick Banks, Chief Executive of Contura said: *"The completion of the 12-month follow-up period for this open label study brings long-term data for Arthrosamid within sight. We have known for some time that Arthrosamid produces impressive results at three-months. Furthermore, the company's 2018 study showed that Arthrosamid maintained its effect in reducing pain for over a year.¹ We are hopeful that the 12-month results from this study will now replicate previously reported results to demonstrate the long-term effectiveness of the product. Results should be available to the company by end 2020."*

About Arthrosamid

Arthrosamid is a polyacrylamide hydrogel developed by Contura as a long-lasting intra-articular injection for the treatment of osteoarthritis in humans. Development of Arthrosamid commenced after the generation of impressive clinical data with Arthramid Vet, a related product of the company, in the treatment of lameness in horses. Arthrosamid becomes embedded in the synovial membrane, providing increased cushioning and other therapeutic benefits to patients with knee osteoarthritis. Patients benefit from both pain relief and improved mobility.

About Osteoarthritis of the Knee

Osteoarthritis is the most common form of arthritis, characterised by pain and physical disability. More than 10% of people over the age of 55 suffer from symptomatic osteoarthritis, primarily involving the knees. Due to the pivotal role of the knee in basic mobility, knee osteoarthritis is associated with significant impairments and limitations in basic activities of daily living, such as walking and moving around, self-care and participation in activities, all contributing to a reduced quality of life. There is a shortage of effective treatments available for knee osteoarthritis today. Even the widely used hyaluronic acids are accepted to have limited efficacy and work for limited duration.

About Contura

Contura is headquartered in London and has its manufacturing facility in Copenhagen, Denmark. It specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily on women's health and pain. Its lead products are Bulkamid®, Arthrosamid®, Aquamid®, Regurin® XL and Cystistat®. Arthrosamid®, the Company's treatment for osteoarthritis of the knee, is the most recent addition to its suite of products and is due to be launched onto the European market in mid-2021. Contura has an established sales and marketing infrastructure in the leading European and worldwide markets. It has its own offices in the UK, United States, Denmark, Germany, France and Italy, currently employing around 55 staff worldwide.

References

1. Henriksen et al. Intra-articular 2.5% polyacrylamide hydrogel for the treatment of knee osteoarthritis: an observational proof-of-concept cohort study. *Clinical and Experimental Rheumatology* 2018.

-ENDS-

Contact:

For further information please contact the Contura Press Office (managed by Trinity PR) on +44 20 7112 4905 / +44 770 948 7959 / jo.hudson@trinitypr.co.uk

www.contura.com